Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Clinical diagnosis of moderate to severe Chronic Obstructive Pulmonary Disease (COPD) as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 Guidelines (mandatory) and including:~* Smoking history of at least 20 pack years~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \< 80% predicted and \>or= 30% of predicted normal value~* Post-bronchodilator FEV1/FVC \< 70%~(Post defined as within 30 minutes of inhalation of 400 µg salbutamol)~Exclusion Criteria:~* Pregnant or nursing (lactating) women and women of child-bearing potential UNLESS they meet pre-specified definitions of post-menopausal or are using pre-specified acceptable methods of contraception~* Hospitalisation for COPD exacerbation in the 6 weeks prior to Visit 1 or during run-in~* Patients requiring oxygen therapy for chronic hypoxemia (typically \>15h/day)~* Respiratory tract infection within 6 weeks prior to Visit 1 and during the run-in period~* Concomitant pulmonary disease~* Asthma history (eosinophils \> 400/mm3; symptoms prior to age 40). Includes history of childhood asthma~* History of long QTc syndrome or QTc interval \> 450 ms for males and \>470 ms for females~* Patients who have a clinically significant condition or a clinically relevant laboratory abnormality~* History of reactions to sympathomimetic amines or inhaled medication~* Inability to use the dry powder devices or perform spirometry~* Irregular day/night, wake/sleep cycles, e.g. shift workers~* Certain medications for COPD and allied conditions such as long acting bronchodilators must not be used prior to Visit 1 and for a pre-specified minimum washout period~* Patients unable or unwilling to complete a patient diary~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg (Type: EXPERIMENTAL): Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.
- Salmeterol 50 μg (Type: ACTIVE_COMPARATOR): Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).